Cardiovascular Health

Latest News


CME Content


One of the most common questions from prescribers that I have answered in the past year concerns how to convert from 1 anticoagulant to anothe

Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals' rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug's safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.

Various health organizations promote the importance of maintaining cardiovascular health because cardiovascular disease (CVD) is the leading cause of death among both men and women in the United States and the number of individuals with CVD continues to escalate annually.